Abstract:
Objective To evaluate the efficacy and safety of flumatinib combined with multi-agent chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Methods The retrospective analysis involved 25 patients with Ph+ALL treated with flumatinib combined with CALLG-2008 chemotherapy at The First Affiliated Hospital of Nanchang University from December 2019 to February 2022. The efficacy and safety of the treatment were statistically analyzed.
Results Among the 25 patients, 21 (84%) and 4 (16%) patients were treated with flumatinib during and after the first induction period, respectively. Complete response (CR) rates at 28 days, 3 months, and 6 months were 88%, 91.67%, and 90.48%, respectively. The respective major molecular response (MMR) rates were 68%, 79.17%, and 80.95% . The respective complete molecular response (CMR) rates were 60%, 75%, and 80.95%. The patients were followed-up with a median follow-up time of 180 days (range, 75.6-458.1 days). The overall survival (OS) and recurrence-free survival (RFS) rates were 82.61% and 73.91%, respectively. During flumatinib treatment, 22 (88%) patients displayed grade Ⅳ myelosuppression. The non-hematologic adverse events mainly included diarrhea, elevated transaminase, fatigue, and nausea. All adverse events improved after treatment.
Conclusions Flumatinib combined with multi-agent chemotherapy is safe and effective in the treatment of patients with Ph+ALL.